AI in Drug Discovery Market

Polaris Market Research presents its latest market research report, titled AI in Drug Discovery Market. It is a comprehensive market research report analyzing the fast-evolving AI in Drug Discovery market. The report offers insight into the current market landscape, drivers for growth, emerging trends, competitive dynamics, and future scope for growth. The study is a combination of qualitative and quantitative analysis, giving insights about the size of the market, segments, regional performance, and industry developments. By going through the report, stakeholders can get an in-depth overview of the AI in Drug Discovery market and its outlook during the forecast period.

The AI in Drug Discovery Market is rapidly evolving as pharmaceutical and biotechnology companies increasingly use artificial intelligence to accelerate research and improve the efficiency of drug development. AI can support target identification, compound screening, molecular analysis, and prediction of drug properties, helping researchers evaluate potential candidates more efficiently. Growing investments in AI driven life sciences and collaborations between technology and pharmaceutical companies are further driving innovation. As the industry looks for faster and more cost effective approaches to drug development, AI is becoming an increasingly important part of the discovery process.

AI in Drug Discovery Market Key Takeaways

• The AI in drug discovery market size was valued at USD 2.29 billion in 2025.
• The market is estimated to reach USD 16.77 billion by 2034.
• The market is projected to witness a CAGR of 24.78% from 2026 to 2034.
• The oncology segment held 29.0% of the market share in 2025.
• The pharmaceutical & biotechnology companies segment is likely to grow at a 25.60% CAGR during the forecast period.
• The North America region held 38.0% of market share in 2025.
• The Asia Pacific region is expected to grow at a 27.40% CAGR from 2026 to 2034.

What is AI in Drug Discovery Market?

AI in drug discovery refers to the application of artificial intelligence and machine learning to identify and develop new drugs. The technology analyzes biological and chemical data to identify targets, screen drug candidates, and predict effectiveness and safety, helping scientists process information far faster than traditional trial-and-error testing while accelerating timelines and reducing R&D costs across the pharmaceutical and biotechnology industries.

Market Dynamics

The report examines the key market dynamics influencing the growth and development of the AI in Drug Discovery market. It analyzes the market drivers, market opportunities, market trends, and restraints that might impact the growth of the market.

Key Market Driver: Pharma-AI Partnerships Accelerate Target Discovery

Pharmaceutical companies are increasingly partnering with AI technology providers to enhance their drug discovery efforts, combining pharma domain expertise with computational power to create more efficient development processes. For instance, Sanofi collaborated with AI company Owkin in June 2026 to build next-generation biopharmaceutical AI agents. Such collaborations are expected to substantially boost market growth as pharma and AI vendors jointly automate and optimize discovery workflows.

Market Opportunity: Growing Adoption of AI in Small and Mid-Sized Biotech Companies

The growing prevalence of AI in drug discovery gives suppliers the opportunity to serve smaller and mid-sized biotech companies that lack in-house research capacity. This allows such companies to work with biological data and screen drugs without large technology teams, enhancing their research potential and enabling them to compete more effectively with larger pharmaceutical companies as adoption widens.

Emerging Market Trend: Generative AI, Multimodal Models, and Predictive Analytics

Continuous advancements in AI, particularly in natural language processing, predictive analytics, and quantum computing, are expanding the capabilities of AI in drug discovery. Generative AI can create novel chemical structures and predict drug-target interactions, while the integration of AI with genomics and proteomics is driving demand for personalized medicine by helping identify biomarkers and customize treatments based on individual genetic profiles.

Market Challenge: High Implementation and Infrastructure Costs

Significant investment is required in hardware, cloud services, software, and skilled personnel to implement AI platforms for drug discovery, posing challenges for smaller organizations. This is compounded by data privacy and cybersecurity concerns around sensitive genomic and clinical trial data, low-quality or fragmented biological data affecting model performance, and regulatory frameworks for AI-based drug development that are still evolving.

Explore The Complete Comprehensive Report Here:

https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market 

How Is Market Segmentation Done?

The market is segmented on the basis of offering (software, services), technology (machine learning, deep learning, supervised learning, reinforcement learning, unsupervised learning, and others), therapeutic area (oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious disease, others), application (drug optimization & repurposing, preclinical testing, others), end user (pharmaceutical & biotechnology companies, contract research organizations, research centers, academic & government institutes), and region.

Which Region Leads Market Demand?

By region, the study covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America led the market with a 38.0% share in 2025, driven by the presence of leading pharmaceutical and biotechnology companies and the rising burden of chronic diseases, with the U.S. accounting for 88.0% of the North America market on the strength of its research ecosystem. Asia Pacific is projected to register the highest CAGR of 27.40% through 2034, supported by rapidly developing healthcare infrastructure, substantial AI investment, and the large, diverse patient populations of China and India that strengthen the region's data resources for AI models.

Who Are the Key Market Players?

The report presents a detailed competitive analysis of the AI in Drug Discovery industry. Player positioning and their strategy, such as new product/service launches, partnerships, mergers and acquisitions, geographic expansion, capacity expansion, technological developments, etc., have been analyzed. The report also examines the competitive structure of the industry and how organizations are responding to changing consumer demands.

A few of the key players in the market include:

• Aitia (formerly GNS Healthcare)
• Atomwise Inc.
• BenevolentAI
• BioSymetrics, Inc.
• BPGbio, Inc.
• Insilico Medicine
• insitro
• Isomorphic Labs (Alphabet Inc.)
• Owkin, Inc.
• Recursion Pharmaceuticals, Inc.
• Schrödinger, Inc.
• XtalPi Inc.

Future Outlook

The AI in drug discovery market is set for high growth through 2034 as pharmaceutical and biotechnology companies increasingly apply AI to reduce costs and accelerate research. Machine learning, generative AI, and predictive analytics will play important roles in target identification and molecule design, with further advances expected in personalized medicine, lab automation, and quantum computing for complex molecular simulations. As collaboration between technology vendors, research institutes, and pharma firms rises and regulatory frameworks mature, AI is expected to play an increasingly central role in developing safer, faster, and more effective therapies worldwide.

More Trending Latest Reports By Polaris Market Research:

Rf Components Market

Stain Remover Products Market

Breast Lesion Localization Market

Freeze Drying Equipment Market

Composite Quartz Stone Market

Composite Quartz Stone Market

Artificial Intelligence in Manufacturing Market

Baby Sitting Services Market

Bone Broth Protein Powder Market